SNDX - NASDAQ
Syndax Pharmaceuticals, Inc.
$18.34
-2.7%Syndax Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are SNDX-5613, which is in phase 1/2 clinical trial targeting the binding interaction of Menin with the mixed lineage leukemia 1 protein for the treatment of MLL-rearranged (MLLr) and nucleophosmin 1 mutant acute myeloid leukemia (NPM1c AML); and SNDX-6352 or axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1, or CSF-1 receptor for the treatment of patients with chronic graft versus host disease (cGVHD). The company is also developing Entinostat. It also has collaborative research and development agreement with National Cancer Institute; a clinical trial agreement with Eastern Cooperative Oncology Group; and a license agreement with Kyowa Hakko Kirin Co., Ltd. Syndax Pharmaceuticals, Inc. was incorporated in 2005 and is headquartered in Waltham, Massachusetts.Massachusetts.
At a Glance
Live SnapshotSyndax Pharmaceuticals, Inc. Management Team
Mr. Michael A. Metzger M.B.A.
Chief Executive Officer & Director
Compensation
$1,240,515
Syndax Pharmaceuticals, Inc. Insider Positioning
During the last 12 months, insiders have purchased $1.71M and sold $781K worth of SNDX shares, resulting in $934K of net buying activity.
3 Months
0
0.00
8.0K
152.38K
-152K
-$152K
3-6 Months
0
0.00
30.1K
628.29K
-628K
-$628K
6-9 Months
157.3K
1.71M
0
0.00
+1.7M
+$1.71M
9-12 Months
0
0.00
0
0.00
+0
+$0
Top Buyers
Metzger Michael A
Director, Officer: Chief Executive Officer
$1.71M
Top Sellers
Metzger Michael A
Director, Officer: Chief Executive Officer
$644K
Goldan Keith A.
Officer: Chief Financial Officer
$137K
Insider Activity Analysis
Net Insider Sentiment
Positive insider sentiment with $934K net buying. Buying activity substantially exceeds selling, indicating insider confidence.
Buy/Sell Ratio
Strong buy/sell ratio. Buying is at least double the selling activity, suggesting robust insider confidence.
Recent Trend (3 Months)
Heavy recent selling activity. Recent insider sales notably exceed purchases—may warrant investigation into company developments.
Insider Participation
2 insider sellers vs. 1 buyers. More insiders selling than buying suggests cautious or negative sentiment.
SEC Filings
SNDX - Filing history and reports
| Filing Type | Filing Date | Period Ending | Fiscal Year | Actions |
|---|---|---|---|---|
DEF 14A DEF 14A 2026 N/A | April 30, 2026 | April 30, 2026 | 2026 | |
DEF 14A DEF 14A 2025 N/A | April 01, 2025 | April 01, 2025 | 2025 | |
DEF 14A DEF 14A 2024 N/A | April 02, 2024 | March 27, 2024 | 2024 | |
DEF 14A DEF 14A N/A | April 07, 2023 | April 07, 2023 | ||
DEF 14A DEF 14A 2022 N/A | March 29, 2022 | May 11, 2022 | 2022 | |
DEF 14A DEF 14A 2021 N/A | April 01, 2021 | May 13, 2021 | 2021 | |
DEF 14A DEF 14A 2020 N/A | April 29, 2020 | June 09, 2020 | 2020 | |
DEF 14A DEF 14A 2019 N/A | April 30, 2019 | June 10, 2019 | 2019 | |
DEF 14A DEF 14A 2018 N/A | April 10, 2018 | May 23, 2018 | 2018 | |
DEF 14A DEF 14A 2017 N/A | April 07, 2017 | May 17, 2017 | 2017 |
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.